281 related articles for article (PubMed ID: 18377417)
1. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma.
Itamochi H; Kigawa J; Terakawa N
Cancer Sci; 2008 Apr; 99(4):653-8. PubMed ID: 18377417
[TBL] [Abstract][Full Text] [Related]
2. Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin.
Kim A; Enomoto T; Serada S; Ueda Y; Takahashi T; Ripley B; Miyatake T; Fujita M; Lee CM; Morimoto K; Fujimoto M; Kimura T; Naka T
Int J Cancer; 2009 Nov; 125(10):2316-22. PubMed ID: 19598262
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary.
Itamochi H; Kigawa J; Akeshima R; Sato S; Kamazawa S; Takahashi M; Kanamori Y; Suzuki M; Ohwada M; Terakawa N
Oncology; 2002; 62(4):349-53. PubMed ID: 12138243
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of autophagy protein LC3A as a therapeutic target in ovarian clear cell carcinomas.
Miyamoto M; Takano M; Aoyama T; Soyama H; Yoshikawa T; Tsuda H; Furuya K
J Gynecol Oncol; 2017 May; 28(3):e33. PubMed ID: 28382796
[TBL] [Abstract][Full Text] [Related]
5. Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary.
Umezu T; Shibata K; Kajiyama H; Yamamoto E; Nawa A; Kikkawa F
J Clin Pathol; 2010 Nov; 63(11):962-6. PubMed ID: 20972242
[TBL] [Abstract][Full Text] [Related]
6. Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: cytoplasmic sequestration of CDK2 by p27.
Itamochi H; Yoshida T; Walker CL; Bartholomeusz C; Aoki D; Ishihara H; Suzuki N; Kigawa J; Terakawa N; Ueno NT
Gynecol Oncol; 2011 Sep; 122(3):641-7. PubMed ID: 21652059
[TBL] [Abstract][Full Text] [Related]
7. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary.
Sasano T; Mabuchi S; Kuroda H; Kawano M; Matsumoto Y; Takahashi R; Hisamatsu T; Sawada K; Hashimoto K; Isobe A; Testa JR; Kimura T
Mol Cancer Res; 2015 Apr; 13(4):795-806. PubMed ID: 25519148
[TBL] [Abstract][Full Text] [Related]
9. The Analysis of Cell Cycle-related Proteins in Ovarian Clear Cell Carcinoma Versus High-grade Serous Carcinoma.
Hazama Y; Moriya T; Sugihara M; Sano R; Shiota M; Nakamura T; Shimoya K
Int J Gynecol Pathol; 2018 Nov; 37(6):516-524. PubMed ID: 29019869
[TBL] [Abstract][Full Text] [Related]
10. Annexin A4 is involved in proliferation, chemo-resistance and migration and invasion in ovarian clear cell adenocarcinoma cells.
Mogami T; Yokota N; Asai-Sato M; Yamada R; Koizume S; Sakuma Y; Yoshihara M; Nakamura Y; Takano Y; Hirahara F; Miyagi Y; Miyagi E
PLoS One; 2013; 8(11):e80359. PubMed ID: 24244679
[TBL] [Abstract][Full Text] [Related]
11. Clear cell carcinoma of the ovary: is there a role of histology-specific treatment?
Takano M; Tsuda H; Sugiyama T
J Exp Clin Cancer Res; 2012 Jun; 31(1):53. PubMed ID: 22655678
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy.
Sugiyama T; Kamura T; Kigawa J; Terakawa N; Kikuchi Y; Kita T; Suzuki M; Sato I; Taguchi K
Cancer; 2000 Jun; 88(11):2584-9. PubMed ID: 10861437
[TBL] [Abstract][Full Text] [Related]
13. Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary.
Itamochi H; Kigawa J; Sugiyama T; Kikuchi Y; Suzuki M; Terakawa N
Obstet Gynecol; 2002 Aug; 100(2):281-7. PubMed ID: 12151151
[TBL] [Abstract][Full Text] [Related]
14. Targeting annexin A4 to counteract chemoresistance in clear cell carcinoma of the ovary.
Kim A; Serada S; Enomoto T; Naka T
Expert Opin Ther Targets; 2010 Sep; 14(9):963-71. PubMed ID: 20673185
[TBL] [Abstract][Full Text] [Related]
15. Clear cell carcinoma compared to serous carcinoma in early ovarian cancer: same prognosis in a large randomized trial.
Timmers PJ; Zwinderman AH; Teodorovic I; Vergote I; Trimbos JB
Int J Gynecol Cancer; 2009 Jan; 19(1):88-93. PubMed ID: 19258948
[TBL] [Abstract][Full Text] [Related]
16. Expression of mitochondrial regulators PGC1α and TFAM as putative markers of subtype and chemoresistance in epithelial ovarian carcinoma.
Gabrielson M; Björklund M; Carlson J; Shoshan M
PLoS One; 2014; 9(9):e107109. PubMed ID: 25243473
[TBL] [Abstract][Full Text] [Related]
17. PDK2 leads to cisplatin resistance through suppression of mitochondrial function in ovarian clear cell carcinoma.
Kitamura S; Yamaguchi K; Murakami R; Furutake Y; Higasa K; Abiko K; Hamanishi J; Baba T; Matsumura N; Mandai M
Cancer Sci; 2021 Nov; 112(11):4627-4640. PubMed ID: 34464482
[TBL] [Abstract][Full Text] [Related]
18. MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.
Bartholomeusz C; Oishi T; Saso H; Akar U; Liu P; Kondo K; Kazansky A; Krishnamurthy S; Lee J; Esteva FJ; Kigawa J; Ueno NT
Mol Cancer Ther; 2012 Feb; 11(2):360-9. PubMed ID: 22144664
[TBL] [Abstract][Full Text] [Related]
19. Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma.
Sung PL; Jan YH; Lin SC; Huang CC; Lin H; Wen KC; Chao KC; Lai CR; Wang PH; Chuang CM; Wu HH; Twu NF; Yen MS; Hsiao M; Huang CY
Oncotarget; 2016 Jan; 7(4):4036-47. PubMed ID: 26716408
[TBL] [Abstract][Full Text] [Related]
20. Galectin-3 may contribute to Cisplatin resistance in clear cell carcinoma of the ovary.
Oishi T; Itamochi H; Kigawa J; Kanamori Y; Shimada M; Takahashi M; Shimogai R; Kawaguchi W; Sato S; Terakawa N
Int J Gynecol Cancer; 2007; 17(5):1040-6. PubMed ID: 17433067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
